Key Metrics 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
KDL Biotech Ltd (KOPDRUGS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532291 NSE: KOPDRUGS Pharmaceuticals & Drugs | Small Cap | KDL Biotech Share Price
BSE Share Price
Not Listed
Not Listed
KDL Biotech Ltd (KOPDRUGS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532291 NSE: KOPDRUGS Pharmaceuticals & Drugs | Small Cap | KDL Biotech Share Price
BSE Share Price
Not Listed
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹5 Cr.
Current Price
₹0
52-Week Low / High
₹2 / 2
TTM EPS
-
TTM Sales
-
Book Value per Share
-
P/E Ratio
Industry PE
53.6
Price to Book (P/B)
Price to Sales (P/S)
EV/EBITDA
Dividend Yield
NAN%
Profitability Efficiency
Return on Equity (ROE)
%
Return on Capital Employed (ROCE)
%
Return on Assets (ROA)
%
Operating Profit Margin
0%
Net Profit Margin
-%
Gross Profit Margin
0%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
-6.83%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
68.86%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
-
Equity
₹24 Cr.
Face Value
₹10
All Time Low / High
₹1.61 / 413.35
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation ⓘ
| Mar'02 | Mar'03 | Mar'04 | Sep'05 | Mar'06 | Sep'07 | Sep'08 | Mar'10 | Mar'11 | Mar'12 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.7% | 6.1% | 2.8% | -21.7% | -5.4% | -0.6% | -11.5% | -15.3% | -101.9% | -108.4% | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 204 | 193 | 124 | 106 | 110 | 113 | 56.8 | 25.6 | 28.4 | 26.5 | 0 |
| Sales YoY Gr. | - | -5.2% | -35.9% | -14.7% | 4.4% | 2.3% | -49.7% | -55% | 11% | -6.8% | - |
| Adj EPS ⓘ | 2.1 | 1.4 | -1.8 | -17.2 | -13.5 | -5.4 | -8.5 | -6 | -23.4 | -7.2 | -5.9 |
| YoY Gr. | - | -31.7% | -228.6% | NA | NA | NA | NA | NA | NA | NA | - |
| BVPS (₹) ⓘ | 35.5 | 36.1 | 35.2 | 6.9 | 0.3 | -0.1 | 16.4 | 6.2 | -17.5 | -24.6 | -42.5 |
| Adj Net Profit ⓘ | 3.4 | 2.4 | -3 | -28.9 | -22.6 | -9 | -20.4 | -14.5 | -56.3 | -17.2 | -14 |
| Cash Flow from Ops. ⓘ | -10.6 | 34.9 | 14.2 | 6.4 | -1.9 | 1.7 | -6.3 | 2.2 | 1.6 | 6.8 | - |
| Debt/CF from Ops. ⓘ | -7.2 | 2 | 5 | 7.9 | -84.3 | 32.2 | -10.2 | 17.7 | 38.4 | 8.9 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -20.3% | -24.9% | -22.5% | -6.8% | ||||
| Adj EPS ⓘ | -214.9% | NA | NA | NA | ||||
| BVPSⓘ | -196% | -343.1% | -214.6% | NA | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'02 | Mar'03 | Mar'04 | Sep'05 | Mar'06 | Sep'07 | Sep'08 | Mar'10 | Mar'11 | Mar'12 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 4.1 | 2.6 | -3.3 | -64.7 | -31.5 | -104 | -104.5 | -70.2 | 573.9 | 34 | 17.6 |
| Op. Profit Mgn % ⓘ | 9.8 | 8.2 | 10.1 | -11.7 | -6.2 | -6.4 | -14.9 | -26.4 | -57.6 | -7.8 | NAN |
| Net Profit Mgn % ⓘ | 1.7 | 1.2 | -2.4 | -27.3 | -20.4 | -8 | -35.9 | -56.5 | -198.1 | -65 | -INF |
| Debt to Equity ⓘ | 0.9 | 0.8 | 0.8 | 1.8 | 3 | -308.8 | 1.6 | 2.6 | -1.4 | -1 | - |
| Working Cap Days ⓘ | 147 | 142 | 182 | 127 | 328 | 129 | 298 | 211 | 166 | 107 | 0 |
| Cash Conv. Cycle ⓘ | 62 | 63 | 58 | 39 | 90 | 22 | -37 | -60 | -56 | -18 | 0 |
Valuation of KDL Biotech - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
No data found!
No data found!
No data found!
No data found!
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
KDL Biotech Ltd FAQs
The current trading price of KDL Biotech on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of KDL Biotech stood at ₹5.14 Cr
The latest P/E ratio of KDL Biotech as of 31-Dec-1969 is 0.00.
The latest P/B ratio of KDL Biotech as of 31-Dec-1969 is -0.05.
The 52-week high of KDL Biotech is ₹2.14 and the 52-week low is ₹2.14.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of KDL Biotech is ₹0.00 ( Cr.) .
Data is not available for this company.
No data found
No data found
About KDL Biotech Ltd
KDL Biotech, formerly known as Kopran Drugs was incorporated on August 12, 1986 as a private limited company. The bulk drugs division of Kopran at Khopoli was demerged and merged into KDL Biotech with effect from January 1, 1998 pursuant to order u/s 391 to 394 of the Companies Act by the Bombay High Court. The company is a joint venture between Kopran of Parijat Enterprises, India and Synpac Kingdom Pharmaceuticals of Koo Group, Taiwan.
KDL has a biotechnology division, which manufactures Penicillin-G acylase, the enzyme used for conversion of penicillin to 6APA. It has also successfully developed Bleomycin, an anti-cancer drug and a cytoxic antibiotic. The products under development include mitomycin, another anti-cancer drug and Vancomycin, an anti- bacterial.
KDL is one of the largest manufacturers of semi synthetic penicillin in Asia. From a 12 tonne per annum capacity in 1982-83, it expanded to a present capacity of 1200 tonnes per annum. The company's plant is approved by UK MCA, US FDA, South African MCC and several countries with strict compliance of GMP and GLP.
Milestones:
2000 - The union had declared a strike at the company's factory situated at Village Savroli, Taluka Khalapur, Khopoli, District Raigad, Maharashtra. The company's major foray into the business of biotechnology based products it was proposed to change the name of the company from Kopran Drugs to KDL Biotech for which necessary approval was been received from Registrar of Companies, Maharashtra, Mumbai. The company is a major producer of semi-synthetic penicillins (SSP) and the enzyme for converting penicillin-G to 6APA.
2001- Crisil downgraded the company's NCDs issue to `BB+' from `BBB'.
Products:
1. Finished Dosage Forms
• Antibiotics/Antibacterial s• Anti-Malarial • Cadiovasculars • Pain Management • Anthelminthics
2. Active Pharmaceutical Ingredients
• Anti-hypertensives • Macrolides • Taste Masked • Cephalosporins
Subsidiary:
• Kopran Research Laboratories
Group companies:
• Oriental Containers • United Shippers • Shinrai Toyota • Claridge Moulded Fibre • Kopran
Alliances:
• Gujarat Themis Biosyn • Kampala Pharmaceutical Industries, Uganda
Strategic Business Units:
• Finished Dosage Forms
• Active Pharmaceutical Ingredients
• Research & Development
• Kopran Laboratories
You have 28 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
